The Efficacy of Nebulized Soluble Mannitol and Comparison with 5% Hypertonic Saline on Pulmonary Function of Children with Cystic Fibrosis

Journal of Comprehensive Pediatrics

ARTICLE

Sadr, Saeed¹  Kiani, Masood²  Rezaei, Mohammad³  Khanbabaee, Ghamartaj¹  Tabatabaee, Seyed Ahmad¹  Hosseini, Amirhossein⁴ 

[1] Department of Pediatric Pulmonology, Shahid Beheshti University of Medical Sciences;Non-Communicable Pediatric Diseases Research Center, Health Research Institute, Babol University of Medical Sciences;Shahid Rajaei Heart Center, Tehran University of Medical Sciences;Hepatology and Nutrition Research Center, Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences

关键词: Children;    Cystic Fibrosis;    Pulmonary Function;    Hypertonic Saline;    Mannitol;   

DOI  :  10.5812/compreped.85616

来源: Kowsarmedical

【 摘 要 】

Background: One of the main aspects of the treatment in patients with cystic fibrosis (CF) is the effective clearing of airway secretions. Inhaled hypertonic saline (HTS) and mannitol are among drugs used for this purpose. There are two forms of mannitol, including dry-powder and soluble form. We used soluble mannitol in this study. Objectives: The aim of this study was to evaluate the effect of inhaled soluble mannitol on the pulmonary function of patients with CF as well as its comparison with 5% HTS. Methods: This clinical trial study was performed on 30 children with CF ≥ 5 years of age who referred to the CF clinic in Mofid Children’s Hospital. Patients were divided into two groups, including soluble mannitol and 5% HTS group. At baseline and two weeks after the treatment, a spirometry test was done and forced expiratory flow in 1 second (FEV1), forced vital capacity (FVC), and Forced expiratory flow between 25% and 75% of forced vital capacity (FEF25 - 75%) were measured. Results: The mean of FEV1, FVC, and FEF25 - 75% in the mannitol group before the treatment were 96 ± 30.5%, 99 ± 27%, and 76.3 ± 36.3%, and after the treatment were 100.5 ± 29%, 103.5 ± 23.7%, and 79.9 ± 37.3%, respectively. The difference of FEV1 before and after mannitol was statistically significant (P = 0.031). The mean of FEV1, FVC, and FEF25 - 75% in 5% HTS group were 96.2 ± 25.5%, 99 ± 19.8% and 77.8 ± 35.6% before the treatment and 95.2 ± 20.1%, 99.3 ± 19.2%, 74.2 ± 29.5% after the treatment. There was no significant difference in 5% HTS group. Conclusions: Inhaled soluble mannitol improved pulmonary function of patients with CF and its effect was better than 5% HTS.

【 授权许可】

Unknown